Mark A. Boyd
Department of Microbiology and Infectious Diseases
Flinders Medical Centre
Adelaide
Australia
Name/email consistency: high
- A febrile illness with generalized papular rash involving the palms and soles. Boyd, M.A., Menon, P., Graves, S., Gordon, D.L. Clin. Infect. Dis. (2007)
- Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Boyd, M.A., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P.I., Uchaipichat, V., Stek, M., Lange, J.M., Phanuphak, P., Cooper, D.A., Udomuksorn, W., Miners, J.O. Pharmacogenet. Genomics (2006)
- Pandemic influenza: clinical issues. Boyd, M., Clezy, K., Lindley, R., Pearce, R. Med. J. Aust. (2006)
- The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. Boyd, M.A., Siangphoe, U., Ruxrungtham, K., Reiss, P., Mahanontharit, A., Lange, J.M., Phanuphak, P., Cooper, D.A., Burger, D.M. J. Antimicrob. Chemother. (2006)
- Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Boyd, M.A., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E.A., Duncombe, C.J., Ubolyam, S., Burger, D.M., Reiss, P., Stek, M., Lange, J., Cooper, D.A., Phanuphak, P. Antivir. Ther. (Lond.) (2006)
- Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. Boyd, M.A., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., Wangsuphachart, S., Krisanachinda, A., Lerdlum, S., Lange, J.M., Phanuphak, P., Cooper, D.A., Reiss, P. J. Infect. Dis. (2006)
- The long-term consequences of antiretroviral therapy: a review. Boyd, M., Reiss, P. J. HIV. Ther (2006)
- Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). Boyd, M.A., Dixit, N.M., Siangphoe, U., Buss, N.E., Salgo, M.P., Lange, J.M., Phanuphak, P., Cooper, D.A., Perelson, A.S., Ruxrungtham, K. J. Infect. Dis. (2006)
- Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. Boyd, M.A., Siangphoe, U., Ruxrungtham, K., Duncombe, C.J., Stek, M., Lange, J.M., Cooper, D.A., Phanuphak, P. HIV Med. (2005)